Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Page 28 of 30
Jan 28, 2026Johnson & Johnson's Darzalex Faspro marks a significant milestone as the first anti-CD38-based regimen approved for newly diagnosed multiple myeloma patients, including those ineligible for stem cell transplantation. This development broadens the therapeutic options for this challenging hematologic cancer.
Jan 28, 2026The BioSpace 2026 Employment Outlook analyzes the current employment trends in the U.S. life sciences sector amid ongoing financial uncertainties. Despite structural pressures from funding constraints and workforce reductions, there are indicators signaling a possible stabilization in hiring and workforce dynamics for the upcoming year.
Jan 27, 2026As global health dynamics evolve, securing drug ingredient supplies is a strategic priority. This post examines the emerging trend of API stockpiling by major biopharma players under government agreements, highlighting the implications of limited transparency in these collaborations.
Jan 24, 2026An investigation into a troubling botulism outbreak has identified powdered whole milk as a possible vector of contamination in ByHeart's infant formula. This development raises significant concerns regarding manufacturing practices, safety screenings, and regulatory oversight of infant nutrition products in the United States. The implications extend to public health policy, pediatric care, and industry standards.
Jan 22, 2026Data from BioSpace underscores the rising competitiveness in biopharma employment, with a majority of both employed and unemployed professionals planning to seek new opportunities in 2026.
Jan 21, 2026In a significant industry move, Pfizer has offloaded its shares in ViiV Healthcare, a key player in HIV therapeutics formed in long-standing partnership with GSK. This article explores the strategic implications for the company and the future outlook for ViiV under GSK's majority control.
Jan 21, 2026The acquisition centers around Rapt Therapeutics’ lead candidate ozureprubart, a long-acting anti-IgE antibody designed to serve as a prophylactic treatment for food allergies. This move positions GSK to compete with existing immunology therapies, including Roche’s blockbuster allergy drug Xolair.
Jan 19, 2026Galapagos, a biotech company with decades of history, has faced turbulent times in recent years. The appointment of Henry Gosebruch as CEO signals a turning point with significant resources at his disposal to redirect the company's trajectory. This article explores the challenges faced by Galapagos, the new leadership’s outlook, and the broader context of the biopharmaceutical industry as it navigates through evolving market dynamics.
Jan 19, 2026Novo Nordisk has marked a notable milestone with the swift adoption of its oral Wegovy drug, signaling a key moment in the competitive landscape of GLP-1 therapies, although rival Eli Lilly leads in sales.
Jan 19, 2026The U.S. life sciences sector exhibited cautious optimism at the end of 2025, with job market indicators suggesting a meaningful shift towards stability. This review explores the key takeaways from BioSpace’s latest quarterly report and what they imply for industry employment trends and economic health.
Jan 17, 2026Pregnant individuals have often faced uncertainty regarding the safety of acetaminophen (Tylenol), one of the most commonly used medications during pregnancy. The latest findings provide reassurance by clarifying that its use is not associated with increased risk of neurodevelopmental disorders in offspring.
Jan 16, 2026In a move to streamline operations and concentrate resources, Vedanta Biosciences, a Cambridge-based biotech company, recently laid off half of its workforce and furloughed many others. This restructuring aims to prioritize the upcoming Phase III study of its lead candidate targeting C. difficile infections.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.